INHALE-3 extension study: Inhaled technosphere insulin plus insulin degludec maintains glycemic control
A new study in the journal Diabetes Technology & Therapeutics evaluated the effects of a regimen of inhaled technosphere ...
EurekAlert!17d
Results of the INHALE-3 extension study: inhaled technosphere insulin plus insulin degludec in T1D
A new study in the peer-reviewed journal Diabetes Technology & Therapeutics (DTT) evaluated the effects of a regimen of inhaled technosphere insulin (TI) and insulin degludec over 30 weeks and its ...
pharmaphorum3y
China's insulin plans will hit 2022 revenues, says Novo Nordisk
The VBP for insulin – which applies to supplies destined for hospitals in China – is expected to be implemented during the first half of 2022, according to Novo Nordisk.